Dare Bioscience, Inc. (DARE)

NASDAQ: DARE · IEX Real-Time Price · USD
-0.04 (-3.25%)
At close: Jul 1, 2022 4:00 PM
-0.01 (-0.84%)
After-hours: Jul 1, 2022 7:09 PM EDT

Company Description

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States.

It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.

The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth.

Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women.

The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Dare Bioscience, Inc.
Dare Bioscience Logo
Country United States
Industry Health Care Equipment & Supplies
Sector Health Care
Employees 20

Contact Details

3655 Nobel Drive
San Diego, CA 92122
United States
Phone 858 926 7655
Website darebioscience.com

Stock Details

Ticker Symbol DARE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001701808
CUSIP Number 15708Q105
ISIN Number US23666P1012
Employer ID 20-4139823
SIC Code 2834

Key Executives

Name Position
Sabrina Martucci Johnson President, Chief Executive Officer, Secretary and Director
Lisa Walters-Hoffert Chief Financial Officer
John A. Fair Chief Strategy Officer
Mark Walters Vice President of Operations
MarDee J. Haring-Layton Vice President of Accounting and Finance
Dr. David Friend Chief Scientific Officer

Latest SEC Filings

Date Type Title
Jul 3, 2017 DFAN14A Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Mar 28, 2017 SC 13D General statement of acquisition of beneficial ownership